TDThibaut Duparc

Thibaut Duparc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thibaut Duparc has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: Comparison with conventional ELISA

    by Annelise Genoux, Thibaut Duparc, Jean-Bernard Ruidavets, Cécile Ingueneau, Souad Najib, Jean Ferrières, Bertrand Perret, Mikaël Croyal, Laurent O. Martinez


  • Open Access

    Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study

    by Thibaut Duparc, Jean-Bernard Ruidavets, Annelise Genoux, Cécile Ingueneau, Souad Najib, Jean Ferrières, Bertrand Perret, Laurent O. Martinez

    HDL-Cholesterol (HDL-C) is not an accurate surrogate marker to measure the cardioprotective functions of HDL in coronary artery diseases (CAD) patients. Hence, measurement of other HDL-related parameters may have prognostic superiority over HDL-C. In this work, we examined the predictive value of HDL particles profile for long-term mortality in CAD patients and to compare its informative value to that of HDL-C and apoA-I. HDL particles profiles were measured by nuclear magnetic resonance (NMR) spectroscopy in 214 male participants with stable CAD (45–74 years). Median follow up was 12.5 years with a 36.4% mortality rate. Cardiovascular mortality accounted for 64.5%. Mean concentrations of total HDL particles (HDL-P), small-sized HDL (SHDL-P) and apoA-I were lower in deceased than in surviving patients whereas no difference was observed according to HDL-C and large HDL particles. All NMR-HDL measures were correlated between themselves and with other HDL markers (HDL-C, apoA-I and LpA-I). In a multivariate model adjusted for cardiovascular risk factors and bioclinical variables, HDL-P and SHDL-P displayed the strongest inverse association with all-cause and cardiovascular mortality. Weaker associations were recorded for apoA-I. Based on our results, we conclude that HDL particle profile measured by NMR spectroscopy should be considered to better stratify risk in population at high risk or in the setting of pharmacotherapy.


  • Open Access

    A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: comparison with conventional ELISA

    by Annelise Genoux, Thibaut Duparc, Jean-Bernard Ruidavets, Cecile Ingueneau, Souad Najib, Jean Ferrieres, Bertrand Perret, Mikael Croyal, Laurent O Martinez

    ATPase inhibitory factor 1 (IF1) is a 9.5 kDa protein that binds to mitochondrial and plasma membrane ATP synthase and selectively inhibits ATP hydrolysis. Recently, IF1 was identified in systemic circulation in humans. IF1 appeared as an independent determinant of HDL-cholesterol with lower levels in coronary heart disease (CHD) patients. Moreover, IF1 was also found to negatively associate with mortality in these patients, supporting the notion that circulating IF1 could be a promising biomarker of cardiovascular disease. However, in previous studies, IF1 was quantified by a non-standardized competitive enzyme-linked immunosorbent assay (ELISA). Herein, we have validated a liquid chromatography-tandem mass spectrometry method (LC-MS/MS) enabling the accurate quantification of IF1 in human plasma. Plasma IF1 was trypsin-digested through an optimized procedure before LC-MS/MS analysis. The method was successfully validated over 4 independent experiments into the range of 100-1,500 ng/mL. Intra- and inter-assay variation coefficients had never exceeded 14.2% and accuracy ranged between 95% and 102% for the selected EAGGAFGK peptide marker. Subsequently, the results of the LC-MS/MS method were compared with those obtained using ELISA in 204 individuals from the GENES study. We found that IF1 plasma levels obtained using both techniques were strongly correlated (r =0.89, p <0.0001), while the Bland-Altman plot did not indicate any major statistically significant differences. To clinically validate LC-MS/MS, we confirmed the positive correlation between IF1 plasma levels and HDL-cholesterol (r =0.38, p <0.0001). Besides, we found lower IF1 plasma levels in CHD patients compared to controls (431 +/- 132 ng/mL and 555 +/- 173 ng/mL, respectively; p <0.0001). Hence, it can be concluded that the presented LC-MS/MS method provides a highly specific strategy for IF1 quantification in human plasma and could be proposed as a reference technique.

  • Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis

    by Thibaut Duparc, François Briand, Charlotte Trenteseaux, Jules Merian, Guillaume Combes, Souad Najib, Thierry Sulpice, Laurent O. Martinez

    Nonalcoholic steatohepatitis (NASH) is an emerging health problem worldwide. However, efficacious pharmacological treatment for NASH is lacking. A major issue for preclinical evaluation of potential therapeutics for NASH is the limited number of appropriate animal models, i.e., models that do not require long-term dietary intervention and adequately mimic disease progression in humans. The present study aimed to evaluate a 3-wk dietary mouse model of NASH and validate it by studying the effects of liraglutide, a compound in advanced clinical development for NASH. C57BL6/J mice were fed a diet high in fat (60%), cholesterol (1.25%), and cholic acid (0.5%), along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC-CDX diet). Histological and biological parameters were measured at 1 and 3 wk. After 1-wk diet induction, liraglutide was administrated daily for 2 wk and then NASH-associated phenotypic aspects were evaluated in comparison with control mice. Prior to treatment with liraglutide, mice fed the HFCC-CDX diet for 1 wk developed liver steatosis and had increased levels of oxidative-stress markers and hepatic and systemic inflammation. For mice not treated with liraglutide, these aspects were even more pronounced after 3 wk of the dietary period, with additional liver insulin resistance and fibrosis. Liraglutide treatment corrected the diet-induced alterations in glucose metabolism and significantly reduced hepatic steatosis and inflammation. This study provides a novel 3-wk dietary model of mice that rapidly develop NASH features, and this model will be suitable for evaluating the therapeutic efficacy of compounds in preclinical drug development for NASH.NEW & NOTEWORTHY We propose a diet high in fat (60%), cholesterol (1.25%), and cholic acid (0.5%) along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC-CDX diet) as a new dietary model of nonalcoholic steatohepatitis. We used the HFCC-CDX model to reproduce the main features of disease development in humans for the purpose of facilitating the rapid screening of drug candidates and prioritizing the more promising candidates for advanced preclinical assessment and subsequent clinical trials.


  • Open Access

    Serum level of High-density lipoprotein particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study

    by Thibaut Duparc, Jean-Bernard Ruidavets, Annelise Genoux, Cécile Ingueneau, Souad Najib, Jean Ferrieres, Bertrand Perret, Laurent O. Martinez

    Background HDL-Cholesterol (HDL-C) is not a right marker to measure the cardioprotective functions of HDL in coronary artery diseases (CAD) patients. Hence, measurement of other HDL-related parameters may have prognostic superiority over HDL-C. This work aimed to examine the predictive value of HDL particles profile for long-term mortality in CAD patients. Its informative value was compared to that of HDL-C and apoA-I. Method NMR spectroscopy HDL particles profile were measured by nuclear magnetic resonance (NMR) spectroscopy in 214 male participants with stable CAD (age 45-74 years). Vital status was yearly assessed, with a median follow up of 12.5 years and a 36.4% mortality rate. Cardiovascular mortality accounted for the majority (64.5 %) of deaths. Results Mean concentrations of HDL particles (HDL-P), small and medium-sized HDL (MS-HDL) and apoA-I were lower in deceased than in surviving patients whereas no difference was observed according to HDL-C and large HDL particles. All NMR-HDL measures were correlated between themselves and with other HDL markers (HDL-C, apoA-I and LpA-I). In a multivariate model adjusted for 14 cardiovascular risk factors and bioclinical variables, HDL-P and MS-HDL-P displayed the strongest inverse association with all-cause and cardiovascular mortality. Weaker associations were recorded for apoA-I. Conclusions HDL particle profile measured by NMR spectroscopy should be considered to better stratify risk in population at high risk or in the setting of pharmacotherapy.

  • Open Access

    Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis

    by Thibaut Duparc, François Briand, Charlotte Trenteseaux, Jules Mérian, Guillaume Combes, Souad Najib, Thierry Sulpice, Laurent O. Martinez

    Aim: Non-alcoholic steatohepatitis (NASH) is an emerging health problem worldwide. However, efficacious pharmacological treatment for NASH is lacking. A major issue for preclinical evaluation of potential therapeutics for NASH is the limited number of appropriate animal models, i.e., models that do not require long-term dietary intervention and adequately mimic disease progression in humans. The present study aimed to evaluate a 3-week dietary mouse model of NASH and to validate it by studying the effects of liraglutide, a compound in advanced clinical development for NASH. Methods: C57BL6/J mice were fed a diet high in fat (60%), cholesterol (1.25%) and cholic acid (0.5%) along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC-CDX diet). Histological and biological parameters were measured at 1 and 3 weeks. Following 1-week diet induction, liraglutide was administrated daily for 2 weeks, and then NASH-associated phenotypic aspects were evaluated in comparison with control mice. Results: Prior to treatment with liraglutide, mice fed the HFCC-CDX diet for 1 week developed liver steatosis and had increased levels of oxidative-stress markers and hepatic and systemic inflammation. For mice not treated with liraglutide, these aspects were even more pronounced after 3 weeks of the dietary period, with additional liver insulin resistance and fibrosis. Liraglutide treatment corrected the diet-induced alterations in glucose metabolism and significantly reduced hepatic steatosis and inflammation. Conclusion: This study provides a novel 3-week dietary model of mice that rapidly develop NASH features, and this model will be suitable for evaluating the therapeutic efficacy of compounds in preclinical drug development for NASH.

  • Genetic deletion of soluble 5′-nucleotidase II reduces body weight gain and insulin resistance induced by a high-fat diet

    by Manuel Johanns, Samanta Kviklyte, Sheng-Ju Chuang, Katrien Corbeels, Roxane Jacobs, Gaëtan Herinckx, Didier Vertommen, Olivier Schakman, Thibaut Duparc, Patrice D. Cani, et al.


  • Pharmacological inhibition of the F1‐ATPase/P2Y1 pathway suppresses the effect of apolipoprotein A1 on endothelial nitric oxide synthesis and vasorelaxation

    by Cendrine Cabou, Paula Honorato, Luis Briceño, Lamia Ghezali, Thibaut Duparc, Marcelo León, Guillaume Combes, Laure Frayssinhes, Audren Fournel, Anne Abot, et al.

    Aim: The contribution of apolipoprotein A1 (APOA1), the major apolipoprotein of high‐density lipoprotein (HDL), to endothelium‐dependent vasodilatation is unclear, and there is little information regarding endothelial receptors involved in this effect. Ecto‐F1‐ATPase is a receptor for APOA1, and its activity in endothelial cells is coupled to adenosine diphosphate (ADP)‐sensitive P2Y receptors (P2Y ADP receptors). Ecto‐F1‐ATPase is involved in APOA1–mediated cell proliferation and HDL transcytosis. Here, we investigated the effect of lipid‐free APOA1 and the involvement of ecto‐F1‐ATPase and P2Y ADP receptors on nitric oxide (NO) synthesis and the regulation of vascular tone.Method: Nitric oxide synthesis was assessed in human endothelial cells from umbilical veins (HUVECs) and isolated mouse aortas. Changes in vascular tone were evaluated by isometric force measurements in isolated human umbilical and placental veins and by assessing femoral artery blood flow in conscious mice.Results: Physiological concentrations of lipid‐free APOA1 enhanced endothelial NO synthesis, which was abolished by inhibitors of endothelial nitric oxide synthase (eNOS) and of the ecto‐F1‐ATPase/P2Y1 axis. Accordingly, APOA1 inhibited vasoconstriction induced by thromboxane A2 receptor agonist and increased femoral artery blood flow in mice. These effects were blunted by inhibitors of eNOS, ecto‐F1‐ATPase and P2Y1 receptor.Conclusions: Using a pharmacological approach, we thus found that APOA1 promotes endothelial NO production and thereby controls vascular tone in a process that requires activation of the ecto‐F1‐ATPase/P2Y1 pathway by APOA1. Pharmacological targeting of this pathway with respect to vascular diseases should be explored.


  • Open Access

    FecalEnterobacterialesenrichment is associated with increased in vivo intestinal permeability in humans

    by Camilla Pedersen, Umer Z. Ijaz, Edith Gallagher, Felicity Horton, Richard J. Ellis, Etana Jaiyeola, Thibaut Duparc, David Russell-Jones, Paul Hinton, Patrice D. Cani, et al.

    Type 2 diabetes (T2D) has been linked with increased intestinal permeability, but the clinical significance of this phenomenon remains unknown. The objective of this study was to investigate the potential link between glucose control, intestinal permeability, diet and intestinal microbiota in patients with T2D. Thirty‐two males with well‐controlled T2D and 30 age‐matched male controls without diabetes were enrolled in a case–control study. Metabolic parameters, inflammatory markers, endotoxemia, and intestinal microbiota in individuals subdivided into high (HP) and normal (LP) colonic permeability groups, were the main outcomes. In T2D, the HP group had significantly higher fasting glucose (P = 0.034) and plasma nonesterified fatty acid levels (P = 0.049) compared with the LP group. Increased colonic permeability was also linked with altered abundances of selected microbial taxa. The microbiota of both T2D and control HP groups was enriched with Enterobacteriales. In conclusion, high intestinal permeability was associated with poorer fasting glucose control in T2D patients and changes in some microbial taxa in both T2D patients and nondiabetic controls. Therefore, enrichment in the gram‐negative order Enterobacteriales may characterize impaired colonic permeability prior to/independently from a disruption in glucose tolerance.